Ketamine use outside of acute pain management and procedural sedation should be part of comprehensive treatment plan by trained medical professionals
Risk particularly heightened in men, but seen across kidney disease stages
Modestly lower risk for depression seen compared with DPP-4i use, but not compared with SGLT-2i use
Findings seen both at baseline and for developing new conditions over time, even when adjusting for sociodemographic and lifestyle factors
Fewer depressive symptoms and better mental health associated with higher psychological resilience
Reproductive health may be the pathway linking traffic-related air pollution to depression
Drug is the first and only approved monotherapy for refractory major depressive disorder
Overall, retirement associated with higher levels of depression
Review shows benefit for cutting risk for onset of major depressive disorder by 42 percent
Association with depression attenuated in later years, while new sociodemographic risk factors emerged